Pegylated rhG-CSF: 6mg

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

Breast CancerFebrile NeutropeniaNSCLCNeutropenia

Phase 3

A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy

Jiangsu HengRui Medicine Co., Ltd.Febrile Neutropenia, Neutropenia, NSCLC

Start: 2012-04-30Target: 150Updated: 2012-11-06

A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy

CompletedNCT01611051

Jiangsu HengRui Medicine Co., Ltd.Breast Cancer, Febrile Neutropenia, Neutropenia

Start: 2012-03-31Target: 330Updated: 2013-01-08

Related Papers

Molecular analysis of cell-free DNA to identify distinct molecular mutational burden and its effect on first-line chemotherapy in patients with NSCLC from a phase III trial.

Journal of Clinical Oncology2017-05-20

Multicenter randomized double-blind controlled phase III study of hhpg-19K as prophylactic therapy in patients with advanced non-small cell lung cancer (NSCLC) receiving myelosuppressive chemotherapy.

Journal of Clinical Oncology2014-05-20